Mvasi®
ACTIVE PRINCIPLE:
Bevacizumab
INDICATION:
Colon or rectal carcinoma
Breast cancer
Non-small cell lung cancer
renal cell cancer
Ovarian, fallopian tube and peritoneal cancer
Cervical cancer
DATE:
15/01/2018
STATUS:
Authorized
ACTIVE PRINCIPLE:
Bevacizumab
INDICATION:
Colon or rectal carcinoma
Breast cancer
Non-small cell lung cancer
renal cell cancer
Ovarian, fallopian tube and peritoneal cancer
Cervical cancer
DATE:
15/01/2018
STATUS:
Authorized